G1 THERAPEUTICS
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.
G1 THERAPEUTICS
Industry:
Biotechnology Developer Platform Medical Therapeutics
Founded:
2008-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.g1therapeutics.com
Total Employee:
101+
Status:
Active
Contact:
+1 919 213 9835
Email Addresses:
[email protected]
Total Funding:
497.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Amazon
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - G1 Therapeutics
Tavistock Life Sciences
Tavistock Life Sciences investment in Series C - G1 Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series C - G1 Therapeutics
Cowen Group
Cowen Group investment in Series C - G1 Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - G1 Therapeutics
Eshelman Ventures
Eshelman Ventures investment in Series C - G1 Therapeutics
Aju IB Investment
Aju IB Investment investment in Series C - G1 Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series C - G1 Therapeutics
Mountain Group Capital
Mountain Group Capital investment in Series C - G1 Therapeutics
Lumira Ventures
Lumira Ventures investment in Series C - G1 Therapeutics
Key Employee Changes
Official Site Inspections
http://www.g1therapeutics.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.34 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "G1 Therapeutics"
G1 Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 919 213 9835 G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.See details»
G1 Therapeutics - Wikipedia
G1 Therapeutics was co-founded in 2008 by Norman Sharpless, 15th Director of the National Cancer Institute, and Kwok-Kin Wong, to develop and commercialize drug candidates discovered at, and licensed from, Sharpless’ lab at the University of North Carolina at Chapel Hill. Early investors in G1 included Hatteras Venture Partners, and Fred Eshelman, founder of PPD, Inc. Other early investors included AstraZeneca’s venture capital fund MedImmune Ventures, and Co…See details»
G1 Therapeutics, Inc. | Optimizing Chemotherapy, Advancing Survival
G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer.See details»
G1 Therapeutics - Overview, News & Similar companies - ZoomInfo
May 23, 2024 G1 Therapeutics contact info: Phone number: (919) 213-9835 Website: www.g1therapeutics.com What does G1 Therapeutics do? Founded in 2008, G1 Therapeutics …See details»
G1 Therapeutics, Inc. Company Profile - Dun & Bradstreet
Company Description: G1 Therapeutics is a biopharmaceutical firm working to develop and delivery of next generation therapies that improve the lives of people affected by cancer. The …See details»
G1 Therapeutics Company Profile | Management and Employees …
SQL International Organization for Standardization . Python Python . Java Oracle . Other Communication and Collaboration Software (4 Technologies) Microsoft Excel Microsoft . ...See details»
G1 Therapeutics, Inc. | LinkedIn
G1 Therapeutics, Inc. | 16,540 followers on LinkedIn. Our mission is to discover, develop and deliver next generation cancer therapies. | G1 Therapeutics, Inc. is a wholly owned subsidiary …See details»
G1 Therapeutics, Inc. Company Overview, Contact Details
Nov 17, 2022 [email protected]: [email protected]: 1%. [email protected]: [email protected]: 1%. See more formats. …See details»
G1 Therapeutics - PitchBook
G1 Therapeutics General Information Description. G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to …See details»
G1 Therapeutics - Craft
Jul 19, 2024 G1 Therapeutics has 5 employees at their 1 location and $82.51 m in annual revenue in FY 2023. See insights on G1 Therapeutics including office locations, competitors, …See details»
G1 Therapeutics, Inc. Information - RocketReach
What is the annual revenue of G1 Therapeutics, Inc.? The G1 Therapeutics, Inc. annual revenue was $24.2 million in 2024.See details»
G1 Therapeutics - Golden
G1 Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina that was founded in 2008 by Kwok-Kin Wong and …See details»
G1 Therapeutics Announces Appointment of Andrew Perry as …
Aug 2, 2021 Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 …See details»
Pharmacosmos Group and G1 Therapeutics Announce Successful …
Following the closing of the tender offer, on September 18, 2024 Purchaser merged with and into G1 Therapeutics, with G1 Therapeutics continuing as the surviving corporation and a wholly …See details»
Working At G1 Therapeutics: Company Overview and Culture
Www.g1therapeutics.com. Organization Type. Public. Social Media. G1 Therapeutics is a clinical stage company developing novel cancer therapies. G1T was founded in 2008 by Drs. Norman …See details»
G1 Therapeutics - VentureRadar
Auto Analyst Score: 56 | g1therapeutics.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times …See details»
G1 Therapeutics Provides Third Quarter 2021 Financial Results and ...
Nov 3, 2021 The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. A live and archived webcast …See details»
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in …
Jun 24, 2024 “The unexpected results from PRESERVE 2 underscore the challenge of developing new therapies for triple negative breast cancer,” said Jack Bailey, Chief Executive …See details»
G1 Therapeutics Provides First Quarter 2020 Corporate and …
Mar 31, 2020 The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 5669692. A live and archived webcast …See details»
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in …
Jun 24, 2024 While not required, it is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the …See details»